Y-mAbs Therapeutics, Inc. (YMAB)
NASDAQ: YMAB · Real-Time Price · USD
5.72
-0.32 (-5.30%)
Feb 21, 2025, 4:00 PM EST - Market closed
Y-mAbs Therapeutics Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Y-mAbs Therapeutics stock have an average target of 21.1, with a low estimate of 11 and a high estimate of 26. The average target predicts an increase of 268.88% from the current stock price of 5.72.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 13, 2025.
Analyst Ratings
The average analyst rating for Y-mAbs Therapeutics stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 5 | 5 | 5 |
| Buy | 3 | 3 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 9 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $22 | Strong Buy | Reiterates | $22 | +284.62% | Jan 13, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates n/a | Strong Buy | Reiterates | n/a | n/a | Dec 11, 2024 |
| Brookline Capital | Brookline Capital | Strong Buy Initiates $17 | Strong Buy | Initiates | $17 | +197.20% | Dec 5, 2024 |
| Oppenheimer | Oppenheimer | Buy Initiates $23 | Buy | Initiates | $23 | +302.10% | Nov 18, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $22 | Strong Buy | Reiterates | $22 | +284.62% | Nov 15, 2024 |
Financial Forecast
Revenue This Year
90.25M
from 84.82M
Increased by 6.41%
Revenue Next Year
106.63M
from 90.25M
Increased by 18.15%
EPS This Year
-0.63
from -0.49
EPS Next Year
-0.63
from -0.63
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 95.6M | 124.4M | 136.3M | |||
| Avg | 90.3M | 106.6M | 116.3M | |||
| Low | 83.1M | 89.3M | 89.6M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 12.7% | 37.8% | 27.8% | |||
| Avg | 6.4% | 18.1% | 9.0% | |||
| Low | -2.0% | -1.1% | -16.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.50 | -0.24 | -0.17 | |||
| Avg | -0.63 | -0.63 | -0.81 | |||
| Low | -0.73 | -0.92 | -1.11 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.